Nordic Oncology Biosimilar Market Size & Outlook, 2026-2034

Nordic Oncology Biosimilar Market Insights

As per Reed Intelligence insights, the Nordic Oncology Biosimilar Market stood at USD 80.2 Million in 2025 and is anticipated to grow to USD 412.89 Million by 2034.
The Nordic market is expected to advance at a CAGR of 19.68% from 2026 through 2034.
In 2025, Monoclonal Antibodies (mAbs) accounted for the highest share of the By Product Type market size.
During the forecast period, Monoclonal Antibodies (mAbs) is set to register the highest growth, making it the most lucrative By Product Type segment.

Other Key Findings

As of 2025, Nordic held 1% of the global Oncology Biosimilar Market size.
By 2034, United States is anticipated to capture the largest share of the global Oncology Biosimilar Market.
In Europe, Germany is expected to lead the regional Oncology Biosimilar Market size by 2034.
United Kingdom will remain the fastest-growing market in Europe, reaching USD 1697.95 Million by 2034.

Report Summary

Report Scope	Details
Base Year for Study	2025
Study Period	2022-2034
Historical Period	2022-2024
Forecast Period	2026-2034
Market Size In 2025	USD 80.2 Million
Market Size In 2034	USD 412.89 Million
Largest segment	Monoclonal Antibodies (mAbs)
Units	Revenue in USD Million
CAGR	19.68% (2026-2034)
Segmnetation Covered
By Product Type	Monoclonal Antibodies (mAbs) Hematopoietic Agents Granulocyte Colony-Stimulating Factor (G-CSF) Immunomodulators
By Cancer Type	Breast Cancer Lung Cancer Colorectal Cancer Cervical Cancer Blood Cancer / Hematological Cancers Other types (e.g., kidney, stomach, brain cancers)
By Route of Administration	Intravenous (IV) Subcutaneous (SC) Others
By Distribution Channel	Hospital Pharmacies Retail Pharmacies Online Pharmacies Others
Report Coverage	Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends

Nordic Oncology Biosimilar Market By Product Type 2026-2034 (USD Million)

By Product Type	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034
Monoclonal Antibodies (mAbs)	XX.x	XX.x	XX.x	33.67	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Hematopoietic Agents	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Granulocyte Colony-Stimulating Factor (G-CSF)	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Immunomodulators	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Total	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x

Source: RI Analysis Company Publications, Primary Interviews.

Nordic Oncology Biosimilar Market By Cancer Type 2026-2034 (USD Million)

By Cancer Type	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034
Breast Cancer	XX.x	XX.x	XX.x	28.21	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Lung Cancer	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Colorectal Cancer	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Cervical Cancer	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Blood Cancer / Hematological Cancers	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Other types (e.g., kidney, stomach, brain cancers)	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Total	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x

Source: RI Analysis Company Publications, Primary Interviews.

Nordic Oncology Biosimilar Market By Route of Administration 2026-2034 (USD Million)

By Route of Administration	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034
Intravenous (IV)	XX.x	XX.x	XX.x	42.77	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Subcutaneous (SC)	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Others	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Total	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x

Source: RI Analysis Company Publications, Primary Interviews.

Nordic Oncology Biosimilar Market By Distribution Channel 2026-2034 (USD Million)

By Distribution Channel	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034
Hospital Pharmacies	XX.x	XX.x	XX.x	35.06	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Retail Pharmacies	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Online Pharmacies	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Others	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Total	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x

Source: RI Analysis Company Publications, Primary Interviews.

Author :

Reed Intelligence Research Team

The Reed Intelligence Research Team brings together over 15+ years of collective experience in market research, data analytics, and strategic consulting. Comprising seasoned analysts, economists, and industry specialists, the team delivers precise, data-driven insights across sectors including technology, healthcare, energy, manufacturing, and consumer goods. By combining domain expertise with modern analytical tools, they ensure each report meets the highest standards of accuracy and relevance.